Application Note: Analytical Power Tools Open Upstream Bioprocessing Bottlenecks
30 January 2019

The blockbuster success of antibody-based therapeutics for autoimmune diseases, inflammatory diseases and immunooncology accelerated the high stakes monoclonal antibody (mAb) development race. The market for therapeutic uses of mAbs was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. In addition, mAb research is underway for therapies to treat neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as antibody/drug conjugates (ADC)— mAbs weaponized with radio-isotopes or cytotoxic agents for specific delivery to a cancer cell target.